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Involvement of Caspases in Proteolytic Cleavage
of Alzheimer's Amyloid-b Precursor Protein
and Amyloidogenic Ab Peptide Formation
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1997). One potential factor contributing to the suscepti-
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Primary human neurons undergoing apoptosis haveSummary
been shown to increase the rate of amyloid-b peptide
formation by 3- to 4-fold (LeBlanc, 1995). We thereforeThe amyloid-b precursor protein (APP) is directly and
tested whether this could be reproduced in a culturedefficiently cleaved by caspases during apoptosis, re-
human neuronal cell line and whether apoptosis inhibi-sulting in elevated amyloid-b (Ab) peptide formation.
tion prevented Ab production. Retinoid-differentiatedThe predominant site of caspase-mediated proteoly-
human neuronal NT2 cells (hNT) induced to undergosis is within the cytoplasmic tail of APP, and cleavage
apoptosis by serum deprivation had a substantially ele-at this site occurs in hippocampal neurons in vivo fol-
vated rate of Ab peptide formation (about 4-fold) (Figurelowing acute excitotoxic or ischemic brain injury. Cas-
1A), and this apoptosis-related increase of Ab formationpase-3 is the predominant caspase involved in APP
was attenuated by a nonselective irreversible caspasecleavage, consistent with its marked elevation in dying
inhibitor. The rate of Ab production in the presence ofneurons of Alzheimer's disease brains and colocaliza-
the caspase inhibitor was restored to the steady-statetion of its APP cleavage product with Ab in senile
levels found in nonapoptotic hNT cells, but it was notplaques. Caspases thus appear to play a dual role in
entirely abolished, indicating that apoptosis enhancesproteolytic processing of APP and the resulting pro-
the pathway leading to Ab generation but is not obliga-pensity for Ab peptide formation, as well as in the ulti-
tory for it to occur. Acute apoptotic induction of themate apoptotic death of neurons in Alzheimer's disease.
neuronal precursor cell line NT2 with camptothecin (Fig-
ure 1B) resulted in oligonucleosomal DNA fragmentationIntroduction
and concomitant maturation of procaspase-3, cleavage
of caspase-3 substrates (such as PARP; poly[ADP-The loss of hippocampal neurons by apoptotic cell death
ribose] polymerase) and a ca. 3.5 kDa reduction in theis a prominent feature of Alzheimer's disease (Smale et
mass of endogenous APP (lane 2). The degree of proteol-
ysis of all three polypeptides was approximately the8 To whom correspondence should be addressed (e-mail: donald_
nicholson@merck.com). same (procaspase-3 5 37% 6 4%; PARP 5 66% 6 9%;
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Figure 1. Involvement of Caspases in APP Cleavage and Escalated Ab Formation
(A) Caspase inhibition ablates escalated amyloid-b peptide production in apoptotic neuronal cells. Retinoic acid±differentiated neuronal NT2
cells (hNT) were cultured in the presence (open circles) or absence (filled circles, filled squares) of serum for 4 days. Half of the serum-deprived
cell cultures were treated with Z-VAD(OMe)-CH2F (100 mM initial dose, 50 mM addition at 24 hr intervals) (filled squares). Ab(1-40) was measured
at the indicated intervals in the resulting cell culture supernatants by sandwich ELISA. The relative rates of Ab production were calculated
once a steady state was achieved (in this case, the slope of the values from days 2±4). A representative experiment (n 5 2) is shown, and
each data point is the average value from triplicate cultures.
(B) Caspase-associated APP proteolysis during apoptosis. NT2 cells were induced to undergo apoptosis with 1 mg/ml camptothecin for 6 hr
in the absence or presence of 33 mM Z-VAD(OMe)-CH2F as indicated. Apoptosis was assessed by oligonucleosomal DNA fragmentation (left
panel). Cell lysates were prepared using urea/SDS, resolved on polyacrylamide gels, then immunoblotted for caspase-3 (right, upper panel),
poly(ADP-ribose) polymerase (right, middle panel), or APP (right, lower panel). A representative experiment (n 5 5) is shown.
(C and D) Proteolytic cleavage of amyloid-b precursor protein by group II caspases in apoptotic cell extracts. (C) [35S]Met-labeled APP was
generated by coupled in vitro transcription/translation then incubated with cytosolic extracts from healthy Jurkat cells (lane 1) or extracts
from cells that were induced to undergo apoptosis by CD-95 (Fas, APO-1) immunoligation (lane 2). Intact APP (p120APP) was cleaved to three
discrete intermediates (DAPP) of approximately 85, 88, and 90 kDa. A representative experiment (n 5 4) is shown. (D) The cleavage of [35S]Met-
labeled APP in apoptotic Jurkat extracts was tested in the presence of the indicated concentrations of tetrapeptide-aldehyde caspase inhibitors
(Ac-YVAD-CHO, filled squares; Ac-DEVD-CHO, open circles; Ac-IETD-CHO, filled circles) and quantified by laser densitometry of the resulting
fluorogram. A representative experiment (n 5 2) is shown.
(E) Cleavage of amyloid-b precursor protein by recombinant caspase-3. [35S]Met-labeled APP was incubated with the indicated concentrations
of recombinant human caspase-3 for 60 min at 378C. APP cleavage was quantified by laser densitometry and used to determine values for
kcat/Km from the relationship St/So5 e2kobs*t, where St is the concentration of substrate (APP) remaining at time t, So is the initial substrate
concentration, and kobs 5 kcat´[caspase-3]/Km. A representative experiment (n 5 2) is shown.
APP 5 44% 6 4%; n 5 5) and in each case was abolished apoptotic phenotype by cleaving a discrete subset of
cellular polypeptides at Asp-x bonds (Alnemri et al.,by coincubation with a caspase inhibitor (lane 3). This
indicates that APP is processed by a caspase-depen- 1996; Nicholson and Thornberry, 1997; Thornberry et
al., 1997). The core substrate recognition motif for cas-dent event during apoptosis and raises the possibility
that caspase cleavage directly contributes to the higher pases is comprised of a tetrapeptide, N-terminal to the
scissile bond (P4-P1), with an Asp in P1 being an absolutepropensity for Ab peptide formation observed in apo-
ptotic cells. requirement for cleavage and the P4 residue being the
major specificity determinant. The caspases normally
exist as dormant proenzymes in healthy cells but areCaspase-3 Directly and Efficiently Cleaves
the Amyloid-b Precursor Protein proteolytically converted to active proteases in re-
sponse to diverse apoptotic stimuli. The potential directOwing to the increase in APP proteolysis and Ab peptide
formation that accompanies neuronal apoptosis, we role of caspases in APP processing was initially tested
by combining [35S]-labeled APP with extracts fromsought to determine whether any of the biochemical
components of the cell death pathway might contribute healthy versus apoptotic Jurkat cells (Figure 1C). Jurkat
cells were initially chosen because they contain multipleto this process. Apoptosis itself is dependent on a family
of cysteine proteases, the caspases, which manifest the caspase family members (caspases-2, -3, -4, -6, -7, -8,
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and -9) that are readily activated during apoptosis (un-
published data). The 120 kDa APP was rapidly pro-
cessed to a triad of smaller polypeptides of approxi-
mately 85±90 kDa. These polypeptides corresponded
in mass to APP processing intermediates observed in
primary human neurons deprived of trophic support
(LeBlanc, 1995; LeBlanc et al., 1996) or in a human neu-
ronal cell line during H2O2-induced apoptosis (Zhang et
al., 1997), suggesting that the in vitro proteolysis of APP
by cell extracts may represent that which occurs in neu-
ronal cells. Similar APP cleavage products were also
generated by apoptotic extracts from other cell types,
including NT2 human neuronal precursor cells and B103
neuroblastoma cells (data not shown). The single APP
cleavage event observed in intact NT2 cells during apo-
ptosis (Figure 1B) suggests that the transmembrane ori-
entation of APP restricts the accessibility of the cleavage
sites to proteolysis and that one of the three cleavage
sites might be more vulnerable in vivo. A protease inhibi-
tor profile indicated that all three cleavage products
arose as a consequence of an E64-insensitive cysteine
protease, a signature for caspases (data not shown).
This was confirmed by the ability of caspase-specific
peptide aldehydes to block APP processing to the 85±90
kDa triad (Figure 1D). The caspase inhibitor, Ac-DEVD-
CHO, was a potent inhibitor of APP processing (IC50 5
1 nM), whereas both Ac-IETD-CHO and Ac-YVAD-CHO
were substantially less effective. Since Jurkat cells con-
Figure 2. Increased Caspase-3 Immunoreactivity in Dying Pyrami-tain members of all three caspase subgroups, these
dal Neurons of CA3 Region of Alzheimer's Brain Hippocampusresults indicate that the group II caspases, which include
Paraffin-embedded sections from an Alzheimer's patient (B) and ancaspase-3 (a key mediator of neuronal apoptosis), pri-
age-matched control (A) were processed for antigen retrieval and
marily account for the APP cleavage observed in apo- peroxidase neutralization then probed with an immunoaffinity-puri-
ptotic cells. Identical results were obtained in neuronal fied antibody raised against the large subunit of human caspase-3
precursor NT2 cells; not surprisingly, since caspase-3 (MF-R280) followed by anti-rabbit-HRP visualization (Vectalabs, UK)
and hematoxylin counterstaining. White arrows indicate healthy,is the major caspase in this cell line ([caspase-3] ≈ 55
caspase-3-negative pyramidal neurons in the control sample show-pM; all other caspases, ,14 pM; unpublished data).
ing little, if any, caspase-3 immunoreactivity. Black arrows indicateCollectively, these results indicate that caspase-3 pre-
caspase-3-positive immunoreactive neurons (brown) in an area sus-
dominantly accounts for APP proteolysis during apopto- ceptible to degeneration and having degenerative morphology (in-
sis. In support of this, the proteolytic cleavage of the cluding ªghostsº) in the Alzheimer's sample. Staining was specific
120 kDa APP to the 85±90 kDa triad could also be repro- as judged by (a) the inability of the antiserum to cross react with any
other human caspase, (b) the absence of staining with preimmuneduced with recombinant caspase-3 (Figure 1E), and an
serum, (c) the ability of antigen preadsorption to abolish immuno-analysis of cleavage kinetics indicates that APP proteol-
staining, and (d) the similarity with results using antibodies derivedysis by caspase-3 occurs with relevant kinetic proper-
from another rabbit (data not shown). The width of each panel corre-
ties (kcat/Km 5 5.14 3 105 M21s21) which are similar to sponds to 140 mm. Identical results were found in brains from other
validated substrates for caspase-3, such as poly(ADP- donors (three Alzheimer's, two controls). The examples shown are
ribose) polymerase (kcat/Km 5 15.6 3 105 M21s21 in the from an 82-year-old female with clinical and postmortem diagnosis
of Alzheimer's disease and an 88-year-old male with no clinicalsame experiment; data not shown). Of the human cas-
abnormalities who died of a pulmonary embolus and whose brainpases tested (caspases-1 to -10 and granzyme B; each
was judged to be neurologically normal.examined at equimolar concentrations under identical
conditions), caspase-3 was the most efficient enzyme
to cleave APP, although minor cleavage also occurred mice, which have a massive defect in neuronal apopto-
with caspases-6 and -8 (data not shown). sis during development, leading to brain enlargement (2-
to 3-fold), supernumerary cell masses, and duplicated
brain structures (Kuida et al., 1996). In Alzheimer's pa-Caspase-3 Levels Are Elevated in Dying Neurons
in Human Alzheimer's Brain tients, we found an elevation of caspase-3 immunoreac-
tivity in dying pyramidal neurons of the hippocampus,If caspase-3 is involved in APP processing and neuronal
apoptosis, it should be present at the sites of Ab produc- including the CA3 region, one of the initial sites of neu-
ronal loss in Alzheimer's disease (Figure 2). This circum-tion and neurodegeneration. Caspase-3 (CPP32, apo-
pain, and Yama) (Fernandes-Alnemri et al., 1994; Nichol- stantial evidence suggests that caspase-3 might medi-
ate or contribute to the death of these cells duringson et al., 1995; Tewari et al., 1995) is one of the key
effector caspases in mammalian cell suicide. Its poten- neurodegeneration and that caspase-3-mediated prote-
olysis of APP may accompany this process as a compo-tial importance in neuronal cell death in particular is
underscored by the phenotype of caspase-3-deficient nent of human Alzheimer's disease pathogenesis.
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Figure 3. Sites of Caspase-Mediated APP Proteolysis
(A) Identification and mutagenic elimination of sites of caspase-mediated proteolysis of amyloid-b precursor protein. The three potential
caspase cleavage sites were identified by [35S]Cys versus [35S]Met differential mapping and mass analysis of caspase-cleaved DN-APP deletion
contructs (data not shown). The putative sites were then confirmed by sequential elimination of the predicted P1 Asp residues by site-directed
mutagenesis (a P1 Asp is essential for caspase recognition). The indicated [35S]Met APP mutant polypeptides were generated by coupled in
vitro transcription/translation, then incubated in the absence (lanes 1, 3, 5, and 7) or presence (lanes 2, 4, 6, and 8) of 8 nM caspase-3. A
representative experiment (n 5 3) is shown.
(B) Location of caspase cleavage sites within the amyloid-b precursor protein in relation to other structural features. Domains and interaction
sites within the amyloid-b precursor protein are summarized. The three sites of caspase proteolysis are indicated on the bottom with the
number referring to the Asp residue corresponding to P1. The region encompassing the Ab peptide is expanded at the top with known
mutations indicated in brackets, including the VKMD653-VNLD653 Swedish mutation (circled).
Identification of Three Principal Sites of cells with APP containing either wild-type or P1 Asp-to-
Ala mutations. (B103 cells were chosen owing to theirCaspase-Mediated APP Proteolysis
We next determined the sites of caspase proteolysis very low levels on endogenous APP, which facilitates
the analysis of transfected site-directed mutants.) Whenwithin the 120 kDa APP polypeptide. This was initially
facilitated by the unusual disposition of Cys residues B103 cells harboring stably transfected wild-type APP
were induced to undergo apoptosis, the caspase-medi-at the amino terminus of APP. Treatment of [35S]Cys-
labeled APP with recombinant caspase-3 generated two ated cleavage at the carboxy-terminal (P4)VEVD720(P1)/A
small [35S]Cys-containing fragments (23 and 25 kDa) and site was observed (Figure 4A, lanes 1 and 2). This cleav-
a larger polypeptide (85 kDa), indicating that two of the age event was entirely eliminated by the triple mutant
caspase cleavage sites were within the first N-terminal (data not shown) or by a D720A point mutant (lanes 5 and
220 amino acids of APP and a third site was present at 6), substantiating the direct involvement of caspases in
about residue 700 (data not shown). The position of APP processing in intact neuronal cells. Nonapoptotic
the latter site was further refined by cleaving an APP cells also cleaved APP at the carboxyl terminus at ca.
construct lacking the N-terminal 220 amino acids (DN- 15% of the rate occurring in apoptotic cells (lane 1 vs.
APP). Within each of the three regions predicted to con- 2), and this was also eliminated by mutation of the P1
tain the caspase cleavage sites by analysis of [35S]Cys Asp (D720A) that is required for caspase recognition (lane
APP and [35S]Met APP fragment sizes, excellent caspase 5). Cleavage at the VEVD720A site is consistent with the
consensus sites (Thornberry et al., 1997) were present: z3.5 kDa reduction in APP observed during apoptosis
(P4)DNVD197(P1)/S, (P4)DYAD219(P1)/G, and (P4)VEVD720(P1)/A in NT2 cells (see Figure 1B, lane 2) and appears, at least
(Figure 3B). That these were the authentic sites of cas- with the cell lines tested, to be the predominant site of
pase proteolysis was confirmed by site-directed muta- caspase proteolysis in intact cells (although APP frag-
genesis of the essential P1 Asp of each site (Figure 3A). ments corresponding to cleavage at the two upstream
The APP triple mutant (APP D197A, D219A, D720A), for exam- sites have been observed by others [Zhang et al., 1997]).
ple, could not be cleaved by recombinant caspases Positive identification of this C-terminal cleavage event
(lanes 7 and 8) or by extracts from apoptotic cells (data was confirmed using a neo epitope antibody that we
not shown). (Equivalent results were observed with the generated for immunohistochemical detection of cas-
small molecular mass counterparts of the fragments pase-generated DC-APP in situ. The antisera was raised
described in Figure 3A [data not shown].) against a synthetic peptide corresponding to the nou-
veau C terminus of DC-APP ([KLH]-CHGVVEVD), then
purified by immunoadsorption to the same peptide andCaspase-Mediated APP Proteolysis Occurs in Intact
Cells, Predominantly at Asp720, and Is Elevated two cycles of immunodepletion with a bridging peptide
corresponding to intact APP (HHGVVEVDAAVTPE). Thisduring Apoptosis
Cleavage at the sites described above was next tested antibody, designated aDCCsp-APP, was confirmed to be
highly specific for the caspase-generated neo epitopein intact cells by stable transfection of B103 neuronal
APP Proteolysis during Neuronal Apoptosis
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Figure 4. Caspase-Dependent Cleavage of Amyloid-b Precursor Protein in Intact Cells during Apoptosis and In Situ Detection of a Caspase-
Generated C-Terminal neo Epitope
(A) C-terminal cleavage of APP during apoptosis in transfected B103 cells. Stable B103 cell lines were generated expressing equivalent
amounts of the full-length wild-type APP (wt, lanes 1 and 2), APP lacking Ala721-Asn751Ðthe C-terminal residues following the Asp720 caspase
cleavage site (DC-APP, lanes 3 and 4)Ð, or full-length APP containing a point mutation to eliminate the Asp720 caspase cleavage site (D720A,
lanes 5 and 6). The cell lines were treated for 2 hr in the absence (lanes 1, 3, and 5) or presence (lanes 2, 4, and 6) of 1 mM staurosporine to
induce apoptosis. Cells and apoptotic corpses were harvested by centrifugation, washed in PBS, and lysed in buffer containing Nonidet P-40.
Intact APP was immunodepleted using a-C21 antibody (raised against the C-terminal 21 amino acids of APP) and protein A-Sepharose
harvesting. The remaining APP fragments were immunoprecipitated using 6E10 antibody (raised against the first 17 residues of the Ab
peptide) with protein G-Sepharose harvesting. After resolution by SDS±PAGE, the C-terminal-truncated APP fragments were visualized by
immunoblotting using 22C11 antibody (raised against the amino terminus of APP). Arrows indicate the migration of the APP product generated
by cleavage after Asp720 (DC-APP) or the equivalent transfection standard (lanes 3 and 4). A representative experiment (n 5 4) is shown.
(B) Specific recognition of a caspase-generated APP neo epitope by aDCCsp-APP. [35S]Met-labeled APP variants were generated by coupled
in vitro transcription/translation (upper panel) then immunoprecipitated (lower panel) using a specific antibody (aDCCsp-APP) that recognizes
the caspase-generated neo epitope that is exposed following cleavage of APP at Asp720. A representative experiment (n 5 2) is shown.
(C) C-terminal cleavage of APP during apoptosis in transfected B103 cells. The B103 stable cell line harboring full-length wild-type APP
(described in [A]) was treated for 2 hr in the absence (lane 1) or presence (lanes 2 and 3) of 1 mM staurosporine to induce apoptosis. Cells
in lane 3 were also treated with 100 mM of the caspase inhibitor, Z-VAD(OMe)-CH2F. Cells and apoptotic corpses were harvested and lysed
as described above. Lysates were then immunoprecipitated with aDCCsp-APP, resolved by SDS±PAGE, and immunoblotted for DC-APP using
22C11. As a positive control, untreated B103 cells harboring DC-APP by stable transfection were processed the same way (lane 4). A
representative experiment (n 5 3) is shown.
(D±I) In situ detection of the caspase-generated DC-APP neo epitope during NT2 cell apoptosis. Subconfluent NT2 cells were induced to
undergo apoptosis by incubation for 4 hr with 1 mg/ml camptothecin (E, F, H, and I) in the absence (E and H) or presence (F and I) of 50 mM
of the caspase inhibitor, Z-VAD(OMe)-CH2F. Control cells (D and G) were treated the same but with vehicle (DMSO) only. After cell harvesting
and fixation, all cells were stained for TUNEL (green) and costained using either an antiserum that recognizes the active form of caspase-3
(D±F; aCsp-3(MF397); red) or the caspase-generated DC-APP neo epitope (G±I; aDCCsp-APP; red). All panels are merged images of TUNEL
(green) and immunoreactivity (red), yielding yellow where coincident. A representative experiment (n 5 2) is shown.
in APP by three criteria: (a) its titer by ELISA was .2000- APP from healthy NT2 cells, but following apoptosis
induction it was able to immunoprecipitate the DC-APPfold selective for the immunizing peptide (corresponding
to DC-APP) versus the bridging peptide harboring the cleavage product (Figure 4C). In the latter case, forma-
tion of immunoprecipitable DC-APP in NT2 cells wassame sequence (which corresponds to intact APP) (see
Experimental Procedures); (b) the antibody could immu- abolished by the presence of a caspase inhibitor (lane
3 vs. 2). Comparable results were obtained by immuno-noprecipitate biosynthetic [35S]APP that was truncated
at the D720 caspase site but not intact APP (Figure 4B); histochemical staining of NT2 cells (Figures 4D±4I). NT2
cells induced to undergo apoptosis with camptothecinand (c) the antibody could not immunoprecipitate intact
Cell
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Figure 5. In Vivo Truncation of APP at the
C-Terminal Caspase Site during Neuronal
Apoptosis following Acute Excitotoxic or
Ischemic Injury
The generation of DC-APP in hippocampal
neurons undergoing apoptosis was exam-
ined in vivo following systemic administration
of the excitotoxin kainic acid (A±F) or tran-
sient global cerebral ischemia (G±L).
Excitotoxic injury. Control (left panels, [A], [C],
and [E]) or kainate-treated SV129 mice (right
panels, [B], [D], and [F]) were euthanized, and
adjacent brain sections were stained for the
caspase-generated APP neo epitope (A and
B; aDCCsp-APP), active caspase-3 (C and D;
aCsp-3[MF397]), or TUNEL (E and F). The CA3
region of the hippocampus is shown in all
panels at the same magnification (bar in [F] 5
100 mm). A representative experiment (n 5 4)
is shown.
Ischemic injury. Transient global ischemia
was produced in rats by 12 min of four-vessel
occlusion followed by reperfusion for the indi-
cated length of time (control animals [G] un-
derwent sham surgical procudures without
ischemia). Sections through the CA1 region
of the hippocampus were stained for the cas-
pase-generated APP neo epitope (G±J and L)
or for TUNEL (K). Magnifications for (G)±(K)
are the same (bar in [K] 5 400 mm), and (L)
is an enlargement (bar 5 75 mm) of the region
outlined in (I). A representative experiment
(n 5 4) is shown.
became TUNEL positive with concomitant positive of a caspase inhibitor (F and I). Collectively, these experi-
ments demonstrate that caspase-mediated proteolysisstaining for active caspase-3 (E) and for the caspase-
generated APP neo epitope (H). All three of these apo- of APP at the C-terminal VEVD720A site occurs during
apoptosis in intact cells. Furthermore, the ability of theptosis-related events were abolished by the presence
APP Proteolysis during Neuronal Apoptosis
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aDCCsp-APP neo epitope antibody to recognize the ter- derived by caspase-mediated proteolysis of APP, in-
creased production of DC-APP in vivo accompanied theminus generated by caspase proteolysis in situ makes
generation of active caspase-3 in apoptotic neurons.it a useful tool for following this cleavage event in vivo.
Caspase-mediated alteration of APP processing after
acute brain injury may in part account for the increasedCaspase-Mediated APP Proteolysis Occurs
susceptiblity to Alzheimer's disease in human patientsin Hippocampal Neurons In Vivo
as well.during Acute Brain Injury
The early loss of hippocampal neurons is a prominent
Caspase-Cleaved APP Colocalizes with Senilefeature in Alzheimer's disease pathogenesis. We there-
Plaques in Human Alzheimer's Brainfore wanted to determine whether caspase-mediated
The relevance of caspase-mediated cleavage of APP forAPP proteolysis could be detected in vivo during hippo-
senile plaque formation was assessed in human patientscampal cell death. Two experimental models of acute
that were diagnosed with late stage Alzheimer's diseasebrain injury, both resulting in the apoptotic loss of hippo-
(Figure 6). Senile plaques and aDCCsp-APP immunoreac-campal neurons, were used to examine these events:
tivity were rarely observed in age-matched control pa-(a) kainic acid (excitotoxic)±induced seizures where CA3
tients that did not suffer from Alzheimer's disease. Inneurons predominantly die, and (b) global cerebral is-
contrast, numerous amyloid-b-positive plaques werechemia in which CA1 neurons perish. These models
observed in hippocampal sections from patients thathave an additional advantage in that acute brain injury
suffered from Alzheimer's disease (B), and aDCCsp-APPis an established risk factor for Alzheimer's disease sus-
immunoreactivity was frequently observed (.90%) inceptibility and may therefore shed light on the molecular
the senile plaques (A). These deposits had a punctatebasis for this increased vulnerability. In the excitotoxic
appearance and were localized within the senile plaquesmodel of neuronal injury (Figures 5A±5F), caspase-medi-
(C); however, it was not possible on morphologicalated APP proteolysis, measured by aDCCsp-APP immu-
grounds to define the cellular phenotype in which thenoreactivity, was not detectable in the CA3 region of
aDCCsp-APP immunoreactivity was located. These find-the hippocampus of control mice (A), whereas intense
ings are consistent with the hypothesis that caspase-aDCCsp-APP immunoreactivity was observed in CA3 neu-
generated DC-APP contributes to plaque formation.rons of SV129 mice 48 hr after administration of kainic
acid (25 mg/kg, s.c.) (B). Consistent with the generation
Caspase-Mediated Proteolysis of APP Increasesof this fragment by a caspase-3-dependent mechanism,
the Rate of Amyloid-b Peptide Formationa pronounced elevation of active caspase-3 immunore-
in Neuronal Cellsactivity was observed in the CA3 region of adjacent
Since APP is cleaved by caspases during neuronal injuryhippocampal tissue sections from animals injected with
in vivo, we next determined whether this had an effectkainic acid (D) but not vehicle (C). TUNEL labeling con-
on the endogenous APP processing pathway leading tofirmed that the CA3 neurons which displayed aDCCsp-
Ab peptide formation. This was tested in stably trans-APP and active caspase-3 immunoreactivity were apo-
fected B103 cells harboring the C-terminal-truncated
ptotic (F). To further establish that caspase-mediated
APP construct (DC-APP) corresponding to the product
APP cleavage occurs in vivo, we determined whether
of caspase proteolysis at the D720 site (Figure 7). From
the apoptotic death of CA1 neurons produced by a brief these cells, Ab peptide production was elevated 5-fold
episode of global ischemia was also accompanied by compared to cells that were stably transfected and ex-
increased production of DC-APP (Figures 5G±5L). Basal pressing identical levels of full-length APP (column 2
aDCCsp-APP immunoreactivity was not observed in the versus 1 at 20 hr, 4 versus 3 at 48 hr). One possible
CA1 region of rats subjected to a sham surgical proce- explanation for this effect, given that caspase proteoly-
dure (G); however, aDCCsp-APP immunoreactivity was sis does not directly account for Ab excision from APP,
clearly visible in vulnerable CA1 neurons 24 hr after is that caspase proteolysis adulterates the normal en-
transient global ischemia produced by 12 min of four- dogenous metabolism of APP and that the truncated
vessel occlusion (H). By comparison to the 24 hr time molecule has a higher propensity for metabolism by an
point, aDCCsp-APP immunolabeling appeared to be more amyloidogenic pathway, perhaps by dissociation of key
intense at 48 hr (I), whereas at 72 hr, immunoreactivity interaction domains contained within the C terminus of
was only seen in a few remaining CA1 neurons (J). The the intact APP polypeptide (summarized in Figure 3B).
time courses for generation of active caspase-3 and It has recently been demonstrated, for example, that the
aDCCsp-APP immunoreactivity were similar in CA1 neu- Shc-like PTB domain of X11 interacts with the NPTY
rons following this short period of global ischemia (data motif at the C terminus of APP and reduces Ab peptide
not shown). In agreement with previous findings which formation by binding to and slowing APP processing
indicate that CA1 neurons undergo apoptosis following (Borg et al., 1998). It is likely that removal of this and
transient global ischemia, TUNEL labeling was elevated other key components of the C terminus of APP biases
in CA1 neurons (K). Under high magnification, aDCCsp- its route of cellular degradation along an amyloidogenic
APP immunoreactivity was apparent in dendritic pro- pathway (Russo et al., 1998).
cesses as well as the cell body of dying CA1 neurons
(L). Taken together, these results indicate that neuronal The Swedish Familial Mutation of APP Markedly
apoptosis in the rodent hippocampus, produced by ei- Improves an Otherwise Poor Caspase Consensus
ther excitotoxic or ischemic injury, is associated with Site in the b-Secretase Region
an elevation in DC-APP formation. Consistent with our in In addition to the three caspase cleavage sites con-
tained within the APP polypeptide, with the dominantvitro findings which indicate that the DC-APP fragment is
Cell
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Figure 7. Caspase-Mediated Generation of DC-APP Results in Ele-
vated Amyloid-b Peptide Formation
The B103 stable cell lines described for Figure 4A, expressing com-
parable levels of full-length APP (wt, columns 1 and 3) or APP lacking
Ala721-Asn751 (the C-terminal residues following the Asp720 caspase
cleavage site [DC-APP, columns 2 and 4]), were cultured in fresh
medium for 20 or 48 hr after which Ab peptide levels in the culture
medium were quantified by immunoassay with monoclonal antibod-
ies. A representative experiment (n 5 4) is shown 6 SD.
with an earlier onset and elevated production of 4 kDa
amyloidogenic Ab peptides (Citron et al., 1992; Cai et
al., 1993; Haass et al., 1995; Holcomb et al., 1998). The
mutation changes the VKMD653 sequence at the b-secre-
tase site to VNLD653, a motif with substantially improved
caspase recognition elements. In particular, the Swed-
ish mutation generates a site that would be preferentially
recognized by group III caspases, especially caspase-6,
as predicted by our positional scanning combinatorial
substrate library (Thornberry et al., 1997). To test this
possibility, fluorogenic tetrapeptides corresponding to
wild-type and Swedish sequences were synthesized
and tested for their ability to be cleaved by recombinant
caspase-6. The in vitro cleavage of VNLD-AMC (Swed-
ish) was markedly higher than the VKMD-AMC (wild-
type) fluorogenic peptide, although lower than a peptide
Figure 6. Colocalization of DC-APP with Amyloid-b in Senile Plaques containing the optimal caspase-6 primary recognition
(A) DC-APP, visualized by aDCCsp-APP immunoreactivity, in the same sequence predicted by the combinatorial library VEHD-
area of the hippocampus as shown in (B). AMC (Figure 8A). A differential also occurred in the con-
(B) Senile plaques identified by amyloid-b immunoreactivity (arrows)
text of the full-length APP polypeptide with cytosolicin the hippocampus of a patient diagnosed with Alzheimer's disease.
extracts from apoptotic cells as well as with recombi-Amyloid-b immunoreactivity was also apparent in the endothelial
nant caspase-6 (Figure 8B). In both cases, the Swedishlining of a blood vessel (arrowhead)
(C) Merged image of the caspase-generated APP neo epitope (red) mutation accelerated the rate of proteolysis at the
and Ab (green), yielding yellow where coincident, illustrates the high b-secretase site (columns 3 and 4), and this cleavage
degree of overlap between DC-APP and amyloid-b immunoreactivi- was entirely abolished by mutation of the P1 Asp (D653A)ties. Similar results were observed in seven clinically diagnosed
that is essential for caspase recognition (columns 5 andAlzheimer's patients (male and female aged 77±91 yr with 5±14 yr
6). The likelihood that the b cleavage activity observedAD diagnosis; 2.3±4.3 hr postmortem harvest) but not in seven age-
in apoptotic cellular extracts is attributable to caspase-6matched control patients (male and female aged 79±91 yr, 2.0±4.0
hr postmortem). The bar in (C) 5 100 mm. was supported by its inhibitor profile (potency of Ac-
IETD-CHO . Ac-DEVD-CHO . Ac-YVAD-CHO), which
is consistent with a group III caspase (which includes
caspase-6) being responsible (data not shown). A mea-processing site being at Asp720 (Figure 3B), at least one
documented familial Alzheimer's disease (FAD) muta- surement of the rate of caspase-6-mediated proteolysis
of the b-secretase site (Figure 8C) indicated that thetion introduces an additional caspase susceptibility site
to the molecule. The ªSwedishº mutation of APP is asso- Swedish mutation improved it as a caspase-6 site within
the APP polypeptide by 3-fold (kcat/Km 5 0.8 3 104 M21s21ciated with an inherited form of Alzheimer's disease
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Figure 8. The Swedish Familial Mutation Improves the b-Secretase Target Region of APP as a Caspase-6 Substrate
(A) Fluorogenic tetrapeptide-aminomethylcoumarins were synthesized, corresponding to either the VKMD653/A654 site at the b-secretase target
region of APP (VKMD-AMC, open circles; see Figure 3B), the Swedish dipeptide mutation (VNLD-AMC, filled circles), or the optimal tetrapeptide
for caspase-6 predicted by a positional scanning combinatorial substrate library (VEHD-AMC, open squares). Their suitability as caspase-6
substrates was tested in reaction mixtures containing recombinant human caspase-6 (2 nM) plus varying concentrations of the fluorogenic
ligands. A representative experiment (n 5 3) is shown.
(B) APP constructs were generated to eliminate the N-terminal caspase cleavage sites (DN-APP), then engineered to contain the wild-type
b-secretase region (VKMD653/A654; columns 1 and 2), the Swedish mutation (VNLD653/A654; columns 3 and 4), or the Swedish mutation with the
P1 Asp that is essential for caspase recognition changed to Ala (VNLA653/A654; columns 5 and 6). [35S]Met-labeled proteins were generated
from these constructs by coupled in vitro transcription/translation, then incubated with cytosolic extracts from apoptotic cells (solid columns;
1, 3, and 5) or recombinant caspase-6 (hashed columns; 2, 4, and 6). The percentage of the input APP that was cleaved in the b-secretase
target region in 60 min was determined by fluorography and is expressed 6 SD. A representative experiment (n 5 5) is shown.
(C and D) Increased susceptibility of the APP b-secretase site to caspase-6 by the Swedish familial mutation and dependence of elevated
amyloid-b peptide formation in cells harboring Swedish APP on the P1 Asp necessary for caspase recognition.
(C) [35S]Met-labeled DN-APP containing either the wild-type b-secretase sequence (open circles) or the Swedish dipeptide mutation (filled
circles) was incubated with the indicated concentrations of recombinant human caspase-6 for 60 min at 378C. Cleavage was quantified by
phosphorimaging of the b cleavage fragment and used to determine values for kcat/Km as described in the legend to Figure 1F.
(D) Stable K562 cell lines were generated harboring full-length APP with the wild-type VKMD653/A654 site, the Swedish mutation (VNLD653/A654),
or the Swedish mutation with the P1 Asp changed to Ala (VNLA653/A654). Identical quantities of cells, expressing equivalent amounts of the APP
constructs, were metabolically labeled by culturing in methionine-free medium for 1 hr then for 5 hr in the presence of [35S]Met. The cells and
medium were separated by centrifugation; then [35S] Ab peptides were immunoprecipitated from each (using 4G8 antibodies), resolved by
SDS±PAGE (10%±20% polyacrylamide; Tricine gels), and visualized by fluorography. A representative experiment (n 5 3) is shown.
for wild-type APP versus 2.2 3 104 M21s21 for APP peptides (Figure 8D). The formation of the amyloido-
genic 4 kDa Ab peptide, but not the 3 kDa Ab peptide,containing the Swedish mutation). Neither the wild-type
APP nor APP containing the Swedish mutation could was dramatically reduced in K562 cells containing
Swedish APP where the P1 Asp necessary for caspasebe cleaved at this site by other caspases, such as
caspase-1, -3, -7, and -8, or by granzyme B (data not proteolysis was eliminated from the b-secretase region
(D653A lane 3 versus 2, lane 6 versus 5). An Ab(1±40)shown), indicating that this event may be restricted to
caspase-6. sandwich Elisa produced identical results (substantially
elevated Ab production in cells harboring the Swedish
mutation [65 6 4 arbitrary units versus undetectableEnhanced Amyloid-b Peptide Formation Occurs
in Cells Harboring the Swedish Mutation levels in cells harboring wild-type APP] and attenuation
by the P1 D653A mutation [16 6 4 arbitrary units]). Similarof APP and Is Dependent on Caspase
Proteolysis at the b-Secretase Site results were found in B103 neuronal cells expressing
the same constructs (intracellular 4 kDa Ab peptide for-The consequences of the Swedish mutation in stably
transfected K562 cells was consistent with that reported mation was ablated, as observed in K562 cells, but alter-
native cleavage to produce a ,4 kDa extracellular Abpreviously (Citron et al., 1992, 1995), including a sub-
stantial elevation in the cellular production of amyloid-b peptide occurred in D653A cell culture supernatants,
Cell
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Experimental Proceduresprobably at Phe656 as reported before (Citron et al., 1995;
data not shown). Taken together, these findings directly
Recombinant Engineeringimplicate a caspase in the enhanced Ab production that
All APP clones were derived from human APP751. Clone designa-
occurs in cells harboring the Swedish mutation of APP. tions below are in the following format: [construct]: [vector]: [insert
Other evidence also supports the possibility that cas- site/insert release]: [sense orientation]: [identifier]. Clones were gen-
pases (specifically caspase-6) may contribute to b-secre- erated, as indicated, by PCR-mediated template modification and
were fully sequenced before use. Clones for in vitro transcription/tase activity, particularly in the Swedish Alzheimer's dis-
translation include the following: [wtAPP751; Met1-Asn751]: [pBIIease mutation. First, although there is heterogeneity in
KS1]: [EcoRI/SmaI ClaI]: [T7]: [MF-UMP#1335], [DN-APP751; Met1-the amino terminus of Ab peptides, some of the peptides
Ala17Gly251-Asn751]: [pBII KS1]: [EcoRI/SmaI ClaI]: [T7]: [MF-
generated correspond to cleavage at the V(K or N)(M or UMP#4476], [APP751; D720A]: [pBII KS1]: [EcoRI/SmaI ClaI]: [T7]:
L)D653/A654 caspase-6 site (Wang et al., 1996). Second, [MF-UMP#4444], [APP751; D219A,D720A]: [pBII KS1]: [EcoRI/SmaI
an analysis of the amino acid residues within APP that ClaI]: [T7]: [MF-UMP#4482], [APP751; D197A,D219A,D720A]: [pBII KS1]:
[EcoRI/SmaI ClaI]: [T7]: [MF-UMP#4540], [APP751-DC; Met1-Asp720]:constitute the minimum recognition region for the ªmajor
[pBII KS1]: [EcoRI ClaI/SmaI ClaI]: [T7]: [MF-UMP#4446], [sigDN-proteaseº that accounts for b-secretase activity (deter-
APP751 VNLD; Met1-Ala17Gly251-Asn751]: [pBII KS1]: [BamHI/ClaI]:mined to be Val650 to Ala654) corresponds exactly with
[T7]: [MF-UMP#4476], [sigDN-APP751 VNLD (Swedish); Met1-the P4-P19 caspase-6 recognition site (Citron et al., 1995). Ala17Gly251-Asn751,K651N,M652L]: [pBII KS1]: [BamHI/ClaI]: [T7]: [MF-
Finally, caspase-6 is present in the hippocampus and UMP#4982], [sigDN-APP751 VNLA; Met1-Ala17Gly251-Asn751,K651N,-
frontal cortex of human Alzheimer's brain samples (as M652L,D653A]: [pBII KS1]: [BamHI/ClaI]: [T7]: [MF-UMP#4983],
well as age-matched controls) at levels that can be [sigDN-APP751 VEHD; Met1-Ala17Gly251-Asn751,K651E,M652H]: [pBII
KS1]: [BamHI/ClaI]: [T7]: [MF-UMP#5165]. Mammalian expressionreadily detected by immunoblotting (data not shown).
clones include the following: [wtAPP751; Met1-Asn751]: [pCEP4]: [NotICollectively, these findings support a role for caspase-6
XmnI-blunt-BamHI]: [CMV]: [MF-UMP#4573], [APP751; D720A]:in the cleavage of APP at the b-secretase region and
[pCEP4]: [NotI XmnI-blunt-BamHI]: [CMV]: [MF-UMP#4575], [APP751;
suggest a caspase-assisted mechanism that accounts D197A,D219A,D720A]: [pCEP4]: [NotI XmnI-blunt-BamHI]: [CMV]: [MF-
for the elevated Ab peptide formation in patients with UMP#4901], [APP751-DC; Met1-Asp720]: [pCEP4]: [NotI ClaI-blunt-
the Swedish familial mutation. BamHI]: [CMV]: [MF-UMP#4577], [APP751 VNLD; K651N,M652L]:
[pCEP4]: [NotI XmnI-blunt-BamHI]: [CMV]: [MF-UMP#5149], [APP751
VNLA; K651N, M652L,D653A]: [pCEP4]: [NotI XmnI-blunt-BamHI]: [CMV]:Conclusion
[MF-UMP#5150].Caspases contribute to the complex proteolytic pro-
cessing of the amyloid-b precursor protein and appear
Stable Cell Linesto contribute to amyloidogenic Ab peptide formation by
To generate stable cell lines, B103 cells (a rat neuronal cell line) orat least two distinct mechanisms. The cleavage of APP
K562 cells (a human erythroleukemia cell line) were transfected with
at endogenous caspase consensus sites [(P4)DNVD197 the indicated pCEP4 plasmid then selected continuously with hygro-
(P1)/S, (P4)DYAD219(P1)/G, and, predominantly, (P4)VEVD720 mycin. Expression levels were determined during the course of each
(P1)/A] probably corrupts the normal intracellular pro- experiment by immunoblotting to verify that each cell line expressed
comparable levels of their respective APP constructs. Cell line des-cessing of APP that would otherwise preclude it from
ignations below are in the following format: [designation]: [ex-Ab peptide formation or accumulation. A ªvicious cycle,º
pressed protein]: [transfection clone]: [selection]: [identifier]. Stableoccurring over a protracted period of time, may there-
cell lines include the following: [B103-APP751]: [wtAPP751; Met1-
fore proceed via the following steps in susceptible neu- Asn751]: [MF-UMP#4573]: [hygro]: [B103:4573; 97106-22], [B103-APP
rons: (a) caspase-3-mediated truncation of APP at the D720A]: [APP751; D720A]: [MF-UMP#4575]: [hygro]: [B103:4575; 97106-
C terminus; (b) adulteration of normal APP processing 22], [B103-APP D197A,D219A,D720A]: [APP751; D197A,D219A,D720A]: [MF-
UMP#4901]: [hygro]: [B103:4901; 97106-43], [B103-APP751-DC]:with shunting of the residual polypeptide toward an amy-
[APP751-DC; Met1-Asp720]: [MF-UMP#4577]: [hygro]: [B103:4577;loidogenic pathway; (c) generation of elevated levels of
97106-22], [K562-APP751]: [wtAPP751; Met1-Asn751]: [MF-UMP#4573]:cytotoxic Ab peptide species, resulting in Ab-induced
[hygro]: [K562:4573; 97106-16b], [K562-APP751 VNLD (Swedish)]:neuronal stress; (d) progressive upregulation and/or ac-
[APP751; K651N,M652L]: [MF-UMP#5149]: [hygro]: [K562:5149; 97106-
tivation of endogenous caspases; and (e) exacerbated 64], [K562-APP751 VNLA]: [APP751; K651N,M652L,D653A]: [MF-
APP proteolysis. Furthermore, elevation in APP levels UMP#5150]: [hygro]: [K562:5150; 97106-64].
(which is susceptible to caspase cleavage) has been
reported in dying motor neurons (Barnes et al., 1998), Generation of Antibodies that Specifically Recognize
potentially feeding more APP into the cycle. An apo- a Caspase-Generated APP neo
ptotic initiation event is not necessarily required for this Epitope (aDCCsp-APP)
Two rabbits were immunized with the peptide NH2-CHGVVEVD-cycle to progress, since caspase proenzymes are cata-
COOH that includes the seven amino acids in APP that precede thelytically competent but at low levels compared to their
caspase cleavage site at aspartic acid 720 as well as an amino-mature counterparts (Muzio et al., 1998; Srinivasula et
terminal cysteine residue to allow coupling to KLH. The rabbits were
al., 1998; Yang et al., 1998). A second mechanism in- boosted three times with the immunizing peptide over a 10 week
volves caspase-6-mediated proteolysis in the b-secre- period. At 10 weeks, the titers against the immunizing peptide (deter-
tase region; a process that is accelerated by residue mined by ELISA and defined as the maximal dilution giving a positive
changes at this site, such as the Swedish dipeptidyl response, arbitrarily set at OD450 5 0.2 using the chromogenic sub-
strate for horseradish peroxidase ABTS) were .1:204,800 andmutation, that improve its susceptibility to this enzyme.
1:12,520. The antisera were pooled and affinity purified by threeIn addition to APP cleavage, caspases have recently
successive chromatographic steps: (1) the antisera was depleted ofbeen implicated in alternative presenilin proteolysis (Kim
immunoglobulins recognizing intact APP by adsorption to a bridging
et al., 1997; Vito et al., 1997). Caspases may thus play peptide that spans the caspase cleavage site (HHGVVEVDAAVTPE)
an important role in both the generation of neurotoxic immobilized on Sepharose 4B (Pharmacia) by cyanogen bromide
Ab peptides as well as in the ultimate death of neurons activation; (2) the flowthrough from step (1) was applied to a Sepha-
rose 4B column containing the immunizing peptide (immobilized toby apoptosis in Alzheimer's disease.
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the support as described in step 1); the column was washed and (pH 7.5) followed by the addition of NaCl to a final concentration of
1 M. After overnight incubation at 48C, the supernatants were clari-the specific antibodies were eluted via a pH gradient and placed in
a borate buffer (0.125 M borate); (3) the eluant from the second fied by centrifugation at 14,000 3 g for 20 min at 48C and treated
with 7 mg/ml DNase-free RNase for 45 min at 378C. The DNA wasstep was absorbed against the immobilized bridging peptide as
described in step 1, and the flowthrough was collected. The ELISA extracted once with phenol/chloroform/isoamyl alcohol (25:24:1,
v/v), isopropanol precipitated, resuspended in loading buffer (30%titer for this antibody preparation was ,1:142,000 (,5 ng/ml) against
the immunizing peptide that corresponds to the caspase-generated [v/v] glycerol, 10 mM EDTA [pH 7.5], 0.05% [w/v] bromophenol blue),
and analyzed by electrophoresis on a 1.2% agarose gel in 13 TAEneo epitope, versus .1:71 (.10 mg/ml) for the bridging peptide that
corresponds to intact APP. (40 mM Tris acetate, 1 mM EDTA [pH 8.3]). Bands were visualized
following ethidium bromide staining.
Immunocytochemical Analysis of the Caspase-Cleaved
Fragment of APP in Apoptotic NT2 Cells
Other Procedures
Subconfluent NT2 cells were incubated with 1 mg/ml campthothecin
Recombinant human caspases were generated as described pre-
in the presence or absence of 50 mM Z-VAD(OMe)-CH2F for 4 hr at viously (Rotonda et al., 1996; Thornberry et al., 1997), and in vitro
378C with 5% CO2. The final concentration of DMSO used to dilute cleavage assays were performed in buffer composed of 50 mM
the camptothecin and Z-VAD(OMe)-CH2F was 0.3% (v/v). As a con- HEPES/KOH (pH 7.0), 10% (w/v) sucrose, 2 mM EDTA, 0.1% (w/v)
trol, cells were incubated with 0.3% (v/v) DMSO alone. The cells
CHAPS, and 5 mM dithiothreitol. Peptide aldehydes and fluorogenic
were detached from the plate with Cell Dissociation Solution (Sigma)
aminomethylcoumarins were prepared by solid phase synthesis es-
and pooled with the culture media (to retain floating apoptotic cells).
sentially as described before (Rano et al., 1997). Z-VAD(OMe)-CH2F,Following centrifugation, the cells were fixed in 10% neutral buffered
a pan-caspase inhibitor (Garcia-Calvo et al., 1998), was purchased
formalin for 10 min at room temperature, washed twice in phos-
from Enzyme Systems Products. NT2 cells (human neuronal precur-
phate-buffered saline, and then centrifuged using a Cytospin cen-
sor) and B103 cells (rat neuronal) were maintained in DMEM con-
trifuge onto poly-L-lysine-coated glass slides (Sigma) and dried
taining antibiotics and 10% (v/v) fetal bovine serum (FBS). Retinoic
overnight. The cells were then costained for TUNEL and either
acid±differentiated NT2 neurons (hNT) were maintained in neuron-
aDCCsp-APP at a dilution of 1/4000 or aCsp-3 (MF397) at a dilution
conditioned medium (Stratagene) except during the course of serum
of 1/3000, essentially as described previously (Black et al., 1998)
deprival experiments when they were cultured in DMEM (6 10% [v/v]
except that the proteinase K treatment was omitted.
FBS). K562 cells (human erythroleukemia) and Jurkat cells (human
T-lymphoid) were maintained in RPMI-1640 containing antibiotics
In Vivo Models of Acute Brain Injury and 10% (v/v) FBS. Apoptosis was induced by CD95 (Fas/APO-1)
All animal procedures conformed to the Guide for the Care and Use ligation using 1 mg/ml anti-Fas antibodies (Jurkats only), with 1 mM
of Experimental Animals (Canadian Council on Animal Care, 1993) staurosporine (all cell lines) or with 1 mg/ml camptothecin (all cell
endorsed by the Medical Research Council of Canada. lines) as indicated. Cell extracts were prepared as described pre-
Kainic Acid Treatment viously (Nicholson et al., 1995).
Adult male mice (C57/B6 3 XJL; 25±30 g; Charles River, MontreÂ al)
were injected with an i.p. bolus of 25 mg/kg of kainic acid. After 48
Acknowledgmentshr, the animals were euthanized with an overdose of pentobarbital
(100 mg/kg i.p.). Brains were harvested, sectioned, and analyzed
We wish to thank Robert Seitz (Research Genetics) for his expertiseas described below.
in the generation and affinity purification of the aDCCsp-APP antibod-Transient Forebrain Ischemia
ies. We are also grateful to Claudio Cuello (McGill University) forAdult male Wistar rats (250±275 g; Charles River, MontreÂ al) were
providing the aAb antibody used to label senile plaques in Alzhei-used for all of the experiments. Transient forebrain ischemia was
mer's disease brains. We are particularly indebted to the Sun Healthproduced using published modifications (Pulsinelli and Buchan,
Research Institute for providing us with outstanding Alzheimer's and1988) of the four-vessel occlusion (4-VO) method (Pulsinelli et al.,
control brain sections for immunohistochemical analysis. F. G. G. is1982). Animals that convulsed during 4-VO, or following reperfusion,
a fellow of the Medical Research Council of Canada.along with those that did not fully develop loss of righting reflex
during ischemia were omitted from the study. In the case of sham-
treated animals, the carotids were exposed but not occluded.
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